Efficacy of tocilizumab for refractory Takayasu arteritis: a retrospective study and literature review View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2021-11-08

AUTHORS

Haiyan Li, Zongwen Shuai

ABSTRACT

To evaluate the efficacy and safety of tocilizumab (TCZ) in the treatment of refractory Takayasu arteritis (TAK). Eleven refractory TAK patients treated with TCZ at the First Affiliated Hospital of Anhui Medical University between 2017 July and 2020 December were respectively analyzed. We also respectively analyzed the studies on TCZ efficacy in patients with TAK, from PubMed/MEDLINE, Elsevier Science Direct between January 2010 and April 2021. The median age of 11 patients was 34(19–46) years. After 3 months of TCZ, a significant drop was found in median NIH (3[2–5] at baseline vs 1[0–2] after 6 months; p < 0.05), ITAS-2010 score (8.5[6–11] vs 6[1–10]; p < 0.05). One (9%) patient experienced relapse during TCZ treatment. After withdrawal of TCZ, one patient (9%) underwent relapse and nine patients (81%) were spared of GC use. In literature review, a total of 211 patients (mean age 35 years) were analyzed, including 80 (38%) Chinese and 169 females (80%). Among the 211 patients, (154 patients) 73% achieved remission after the last infusion of TCZ; TAK relapsed in 6% of patients during TCZ treatment and 5% of the TCZ patients after the withdrawal of TCZ. A total of 95 types of adverse events were observed in the literature. Infection was the most common adverse effect, occurring in 50% of patients. TCZ could serve as an efficacious and safe agent for refractory TAK. More... »

PAGES

884-894

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00380-021-01981-1

DOI

http://dx.doi.org/10.1007/s00380-021-01981-1

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1142439886

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/34750666


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal, Humanized", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Recurrence", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Takayasu Arteritis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Rheumatology and Immunology, The First Affiliated Hospital of Anhui Medical University, 230022, Hefei, China", 
          "id": "http://www.grid.ac/institutes/grid.412679.f", 
          "name": [
            "Department of Rheumatology and Immunology, The First Affiliated Hospital of Anhui Medical University, 230022, Hefei, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Li", 
        "givenName": "Haiyan", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Rheumatology and Immunology, The First Affiliated Hospital of Anhui Medical University, 230022, Hefei, China", 
          "id": "http://www.grid.ac/institutes/grid.412679.f", 
          "name": [
            "Department of Rheumatology and Immunology, The First Affiliated Hospital of Anhui Medical University, 230022, Hefei, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shuai", 
        "givenName": "Zongwen", 
        "id": "sg:person.0623105737.61", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0623105737.61"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s11046-004-5495-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011536925", 
          "https://doi.org/10.1007/s11046-004-5495-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s13075-021-02529-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1138169894", 
          "https://doi.org/10.1186/s13075-021-02529-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s13075-020-02311-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1130923476", 
          "https://doi.org/10.1186/s13075-020-02311-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrrheum.2010.82", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017664931", 
          "https://doi.org/10.1038/nrrheum.2010.82"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10067-020-05066-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1127472617", 
          "https://doi.org/10.1007/s10067-020-05066-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11547-019-01058-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1117617323", 
          "https://doi.org/10.1007/s11547-019-01058-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10067-020-05005-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1125452605", 
          "https://doi.org/10.1007/s10067-020-05005-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12026-021-09194-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1138732016", 
          "https://doi.org/10.1007/s12026-021-09194-4"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2021-11-08", 
    "datePublishedReg": "2021-11-08", 
    "description": "To evaluate the efficacy and safety of tocilizumab (TCZ) in the treatment of refractory Takayasu arteritis (TAK). Eleven refractory TAK patients treated with TCZ at the First Affiliated Hospital of Anhui Medical University between 2017 July and 2020 December were respectively analyzed. We also respectively analyzed the studies on TCZ efficacy in patients with TAK, from PubMed/MEDLINE, Elsevier Science Direct between January 2010 and April 2021. The median age of 11 patients was 34(19\u201346) years. After 3 months of TCZ, a significant drop was found in median NIH (3[2\u20135] at baseline vs 1[0\u20132] after 6\u00a0months; p\u2009<\u20090.05), ITAS-2010 score (8.5[6\u201311] vs 6[1\u201310]; p\u2009<\u20090.05). One (9%) patient experienced relapse during TCZ treatment. After withdrawal of TCZ, one patient (9%) underwent relapse and nine patients (81%) were spared of GC use. In literature review, a total of 211 patients (mean age 35\u00a0years) were analyzed, including 80 (38%) Chinese and 169 females (80%). Among the 211 patients, (154 patients) 73% achieved remission after the last infusion of TCZ; TAK relapsed in 6% of patients during TCZ treatment and 5% of the TCZ patients after the withdrawal of TCZ. A total of 95 types of adverse events were observed in the literature. Infection was the most common adverse effect, occurring in 50% of patients. TCZ could serve as an efficacious and safe agent for refractory TAK.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00380-021-01981-1", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1095887", 
        "issn": [
          "0910-8327", 
          "1615-2573"
        ], 
        "name": "Heart and Vessels", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "5", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "37"
      }
    ], 
    "keywords": [
      "refractory Takayasu arteritis", 
      "Takayasu arteritis", 
      "TCZ treatment", 
      "safety of tocilizumab", 
      "patient experienced relapse", 
      "efficacy of tocilizumab", 
      "common adverse effects", 
      "First Affiliated Hospital", 
      "Anhui Medical University", 
      "PubMed/MEDLINE", 
      "Elsevier Science Direct", 
      "TCZ efficacy", 
      "underwent relapse", 
      "TCZ patients", 
      "experienced relapse", 
      "TAK patients", 
      "median age", 
      "adverse events", 
      "GC use", 
      "last infusion", 
      "retrospective study", 
      "Affiliated Hospital", 
      "tocilizumab", 
      "safe agent", 
      "patients", 
      "Medical University", 
      "literature review", 
      "adverse effects", 
      "Science Direct", 
      "arteritis", 
      "relapse", 
      "efficacy", 
      "treatment", 
      "withdrawal", 
      "total", 
      "significant drop", 
      "remission", 
      "review", 
      "MEDLINE", 
      "hospital", 
      "infusion", 
      "infection", 
      "months", 
      "age", 
      "scores", 
      "NIH", 
      "ITAS", 
      "study", 
      "females", 
      "safety", 
      "years", 
      "agents", 
      "Direct", 
      "events", 
      "effect", 
      "use", 
      "literature", 
      "types", 
      "University", 
      "drop"
    ], 
    "name": "Efficacy of tocilizumab for refractory Takayasu arteritis: a retrospective study and literature review", 
    "pagination": "884-894", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1142439886"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00380-021-01981-1"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "34750666"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00380-021-01981-1", 
      "https://app.dimensions.ai/details/publication/pub.1142439886"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-05-10T10:31", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220509/entities/gbq_results/article/article_899.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00380-021-01981-1"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00380-021-01981-1'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00380-021-01981-1'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00380-021-01981-1'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00380-021-01981-1'


 

This table displays all metadata directly associated to this object as RDF triples.

196 TRIPLES      22 PREDICATES      103 URIs      87 LITERALS      16 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00380-021-01981-1 schema:about N0247a27112bb42cbaa4288761b8d5aa1
2 N0c7cd48d945b4827b93583eb8874c8eb
3 N1b001858c78f49bf941505f3db29291d
4 N588285d9b5354148ad732bfe6d2bf662
5 N5f6977ddf3134f14a009bbd4c1229175
6 N9323653c18d54b7ab1c74df940c54a03
7 Nbe6fee83d7a94590b8f9276cc18dd02b
8 Nc600c43eebd1440f8a83e2597a51515f
9 Ne337317901094c73a8460c6ddf3e7e8e
10 anzsrc-for:11
11 anzsrc-for:1103
12 schema:author N8d798573867a47528c7ba38dc6369936
13 schema:citation sg:pub.10.1007/s10067-020-05005-7
14 sg:pub.10.1007/s10067-020-05066-8
15 sg:pub.10.1007/s11046-004-5495-0
16 sg:pub.10.1007/s11547-019-01058-0
17 sg:pub.10.1007/s12026-021-09194-4
18 sg:pub.10.1038/nrrheum.2010.82
19 sg:pub.10.1186/s13075-020-02311-y
20 sg:pub.10.1186/s13075-021-02529-4
21 schema:datePublished 2021-11-08
22 schema:datePublishedReg 2021-11-08
23 schema:description To evaluate the efficacy and safety of tocilizumab (TCZ) in the treatment of refractory Takayasu arteritis (TAK). Eleven refractory TAK patients treated with TCZ at the First Affiliated Hospital of Anhui Medical University between 2017 July and 2020 December were respectively analyzed. We also respectively analyzed the studies on TCZ efficacy in patients with TAK, from PubMed/MEDLINE, Elsevier Science Direct between January 2010 and April 2021. The median age of 11 patients was 34(19–46) years. After 3 months of TCZ, a significant drop was found in median NIH (3[2–5] at baseline vs 1[0–2] after 6 months; p < 0.05), ITAS-2010 score (8.5[6–11] vs 6[1–10]; p < 0.05). One (9%) patient experienced relapse during TCZ treatment. After withdrawal of TCZ, one patient (9%) underwent relapse and nine patients (81%) were spared of GC use. In literature review, a total of 211 patients (mean age 35 years) were analyzed, including 80 (38%) Chinese and 169 females (80%). Among the 211 patients, (154 patients) 73% achieved remission after the last infusion of TCZ; TAK relapsed in 6% of patients during TCZ treatment and 5% of the TCZ patients after the withdrawal of TCZ. A total of 95 types of adverse events were observed in the literature. Infection was the most common adverse effect, occurring in 50% of patients. TCZ could serve as an efficacious and safe agent for refractory TAK.
24 schema:genre article
25 schema:inLanguage en
26 schema:isAccessibleForFree true
27 schema:isPartOf N6c7013ad98b241a5b0d7bb3a727a0f09
28 Na3c7c3f02b7e4180a1a8446e8390f719
29 sg:journal.1095887
30 schema:keywords Affiliated Hospital
31 Anhui Medical University
32 Direct
33 Elsevier Science Direct
34 First Affiliated Hospital
35 GC use
36 ITAS
37 MEDLINE
38 Medical University
39 NIH
40 PubMed/MEDLINE
41 Science Direct
42 TAK patients
43 TCZ efficacy
44 TCZ patients
45 TCZ treatment
46 Takayasu arteritis
47 University
48 adverse effects
49 adverse events
50 age
51 agents
52 arteritis
53 common adverse effects
54 drop
55 effect
56 efficacy
57 efficacy of tocilizumab
58 events
59 experienced relapse
60 females
61 hospital
62 infection
63 infusion
64 last infusion
65 literature
66 literature review
67 median age
68 months
69 patient experienced relapse
70 patients
71 refractory Takayasu arteritis
72 relapse
73 remission
74 retrospective study
75 review
76 safe agent
77 safety
78 safety of tocilizumab
79 scores
80 significant drop
81 study
82 tocilizumab
83 total
84 treatment
85 types
86 underwent relapse
87 use
88 withdrawal
89 years
90 schema:name Efficacy of tocilizumab for refractory Takayasu arteritis: a retrospective study and literature review
91 schema:pagination 884-894
92 schema:productId N15fca3c356c54c4fbb80b0937b53c5c9
93 N9af6f2ca35a7418d98cb21a8e5cd4a23
94 Na726dfc94ac244d9b7709b9eede2269f
95 schema:sameAs https://app.dimensions.ai/details/publication/pub.1142439886
96 https://doi.org/10.1007/s00380-021-01981-1
97 schema:sdDatePublished 2022-05-10T10:31
98 schema:sdLicense https://scigraph.springernature.com/explorer/license/
99 schema:sdPublisher N409956c92ed94d5a8b813638a8f714ff
100 schema:url https://doi.org/10.1007/s00380-021-01981-1
101 sgo:license sg:explorer/license/
102 sgo:sdDataset articles
103 rdf:type schema:ScholarlyArticle
104 N0247a27112bb42cbaa4288761b8d5aa1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Middle Aged
106 rdf:type schema:DefinedTerm
107 N0c7cd48d945b4827b93583eb8874c8eb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Adult
109 rdf:type schema:DefinedTerm
110 N103297f5a97e4c4db55aa1df1ca53716 schema:affiliation grid-institutes:grid.412679.f
111 schema:familyName Li
112 schema:givenName Haiyan
113 rdf:type schema:Person
114 N15fca3c356c54c4fbb80b0937b53c5c9 schema:name dimensions_id
115 schema:value pub.1142439886
116 rdf:type schema:PropertyValue
117 N1b001858c78f49bf941505f3db29291d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Antibodies, Monoclonal, Humanized
119 rdf:type schema:DefinedTerm
120 N409956c92ed94d5a8b813638a8f714ff schema:name Springer Nature - SN SciGraph project
121 rdf:type schema:Organization
122 N477478bede034988a952446d63507e98 rdf:first sg:person.0623105737.61
123 rdf:rest rdf:nil
124 N588285d9b5354148ad732bfe6d2bf662 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Treatment Outcome
126 rdf:type schema:DefinedTerm
127 N5f6977ddf3134f14a009bbd4c1229175 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Retrospective Studies
129 rdf:type schema:DefinedTerm
130 N6c7013ad98b241a5b0d7bb3a727a0f09 schema:issueNumber 5
131 rdf:type schema:PublicationIssue
132 N8d798573867a47528c7ba38dc6369936 rdf:first N103297f5a97e4c4db55aa1df1ca53716
133 rdf:rest N477478bede034988a952446d63507e98
134 N9323653c18d54b7ab1c74df940c54a03 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Recurrence
136 rdf:type schema:DefinedTerm
137 N9af6f2ca35a7418d98cb21a8e5cd4a23 schema:name doi
138 schema:value 10.1007/s00380-021-01981-1
139 rdf:type schema:PropertyValue
140 Na3c7c3f02b7e4180a1a8446e8390f719 schema:volumeNumber 37
141 rdf:type schema:PublicationVolume
142 Na726dfc94ac244d9b7709b9eede2269f schema:name pubmed_id
143 schema:value 34750666
144 rdf:type schema:PropertyValue
145 Nbe6fee83d7a94590b8f9276cc18dd02b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Humans
147 rdf:type schema:DefinedTerm
148 Nc600c43eebd1440f8a83e2597a51515f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Takayasu Arteritis
150 rdf:type schema:DefinedTerm
151 Ne337317901094c73a8460c6ddf3e7e8e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Female
153 rdf:type schema:DefinedTerm
154 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
155 schema:name Medical and Health Sciences
156 rdf:type schema:DefinedTerm
157 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
158 schema:name Clinical Sciences
159 rdf:type schema:DefinedTerm
160 sg:journal.1095887 schema:issn 0910-8327
161 1615-2573
162 schema:name Heart and Vessels
163 schema:publisher Springer Nature
164 rdf:type schema:Periodical
165 sg:person.0623105737.61 schema:affiliation grid-institutes:grid.412679.f
166 schema:familyName Shuai
167 schema:givenName Zongwen
168 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0623105737.61
169 rdf:type schema:Person
170 sg:pub.10.1007/s10067-020-05005-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1125452605
171 https://doi.org/10.1007/s10067-020-05005-7
172 rdf:type schema:CreativeWork
173 sg:pub.10.1007/s10067-020-05066-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1127472617
174 https://doi.org/10.1007/s10067-020-05066-8
175 rdf:type schema:CreativeWork
176 sg:pub.10.1007/s11046-004-5495-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011536925
177 https://doi.org/10.1007/s11046-004-5495-0
178 rdf:type schema:CreativeWork
179 sg:pub.10.1007/s11547-019-01058-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1117617323
180 https://doi.org/10.1007/s11547-019-01058-0
181 rdf:type schema:CreativeWork
182 sg:pub.10.1007/s12026-021-09194-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1138732016
183 https://doi.org/10.1007/s12026-021-09194-4
184 rdf:type schema:CreativeWork
185 sg:pub.10.1038/nrrheum.2010.82 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017664931
186 https://doi.org/10.1038/nrrheum.2010.82
187 rdf:type schema:CreativeWork
188 sg:pub.10.1186/s13075-020-02311-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1130923476
189 https://doi.org/10.1186/s13075-020-02311-y
190 rdf:type schema:CreativeWork
191 sg:pub.10.1186/s13075-021-02529-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1138169894
192 https://doi.org/10.1186/s13075-021-02529-4
193 rdf:type schema:CreativeWork
194 grid-institutes:grid.412679.f schema:alternateName Department of Rheumatology and Immunology, The First Affiliated Hospital of Anhui Medical University, 230022, Hefei, China
195 schema:name Department of Rheumatology and Immunology, The First Affiliated Hospital of Anhui Medical University, 230022, Hefei, China
196 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...